The U.S. stock market is experiencing a notable upswing, with the S&P 500 on track for its longest winning streak since 2004, buoyed by strong employment data and potential trade talks between the U.S ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of its ...

Data from Mirum studies presented at DDW, EASL, and ESPGHAN congresses "We are excited to see the continued evidence ...

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%. The company’s lead product is Livmarli (maralixibat ...

Mirum Pharmaceuticals, Inc. is headquartered just outside of San Francisco in Foster City, CA. This commercial stage concern is focused in debilitating rare and orphan diseases within its pipeline ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced ...

All the Latest Game Footage and Images from Mirum Orbis Mirum Orbis - The Lands of Otium, is a 2D MMORPG created by the french video game studio Askilian Studio. Created since April 2022 ...

28-week data from Phase 2b VANTAGE PBC study highlighting improvements in itch and fatigue will be presented at EASL – Data from Mirum studies presented at DDW, EASL, and ESPGHAN congresses FOSTER ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ...